Seattle
CMC Biologics has completed construction of a disposable biopharmaceutical manufacturing facility in Seattle. The project will support early-phase clinical production of mammalian cell culture-based recombinant proteins. The single-use facility represents a trend in bioprocessing to eliminate the costly sterilization procedures associated with traditional steel tank manufacturing, as well as decrease cross-contamination risks, by utilizing disposable processing equipment and bioreactors.
